Zacks Investment Research upgraded shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) from a hold rating to a buy rating in a research note issued to investors on Friday morning. They currently have $2.25 price target on the stock.

According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “

A number of other research analysts have also issued reports on the stock. HC Wainwright restated a buy rating and issued a $19.50 target price on shares of Rexahn Pharmaceuticals in a report on Monday, November 6th. ValuEngine upgraded shares of Rexahn Pharmaceuticals from a strong sell rating to a sell rating in a report on Thursday, November 2nd. Seaport Global Securities restated a buy rating and issued a $13.00 target price on shares of Rexahn Pharmaceuticals in a report on Friday, October 6th. Finally, Ifs Securities restated an outperform rating on shares of Rexahn Pharmaceuticals in a report on Monday, August 7th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $13.65.

Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) opened at $2.04 on Friday. Rexahn Pharmaceuticals has a 1 year low of $0.38 and a 1 year high of $7.10.

ILLEGAL ACTIVITY NOTICE: “Rexahn Pharmaceuticals, Inc. (RNN) Lifted to Buy at Zacks Investment Research” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/rexahn-pharmaceuticals-inc-rnn-lifted-to-buy-at-zacks-investment-research/1701922.html.

Several hedge funds and other institutional investors have recently bought and sold shares of RNN. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Rexahn Pharmaceuticals in the 3rd quarter worth approximately $119,000. Sabby Management LLC purchased a new position in Rexahn Pharmaceuticals in the 2nd quarter worth approximately $706,000. Renaissance Technologies LLC boosted its holdings in Rexahn Pharmaceuticals by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock worth $2,937,000 after acquiring an additional 862,000 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in Rexahn Pharmaceuticals in the 2nd quarter worth approximately $2,905,000.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Get a free copy of the Zacks research report on Rexahn Pharmaceuticals (RNN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEMKT:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.